Cellistic Introduces Echo™-NK Platform to Power Scalable Off-the-Shelf NK Cell Therapies for Cancer and Autoimmune Diseases

Cellistic, a pioneer in induced pluripotent stem cells (iPSC)-based cell therapies, is launching the Echo™-NK platform to enable the scalable manuf...

April 11, 2025 | Friday | News
AbbVie’s RINVOQ® Becomes First Oral JAK Inhibitor Approved in EU for Giant Cell Arteritis

AbbVie announced that the European Commission (EC) granted marketing authorization to RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment ...

April 10, 2025 | Thursday | News
Gift of Life Biologics and Cellex Cell Professionals Celebrate Ongoing Success of Collaborative Partnership in Cell and Gene Therapy

Gift of Life Biologics, a leading supplier of high-quality cellular starting materials in the US, and Cellex Cell Professionals, a trusted Contract De...

April 08, 2025 | Tuesday | News
Halozyme’s ENHANZE® Technology Powers European Approval of Subcutaneous RYBREVANT® for Advanced NSCLC Treatment

 Halozyme Therapeutics, Inc.announced that Janssen-Cilag International NV, a Johnson & Johnson company, has received European Commission (EC) mark...

April 08, 2025 | Tuesday | News
ABL Bio and GSK Forge Licensing Agreement to Develop Innovative Neurodegenerative Disease Treatments Using BBB Shuttle Platform

ABL Bio Inc. a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a wor...

April 07, 2025 | Monday | News
AstraZeneca’s Imfinzi (Durvalumab) Gains European Union Approval for Resectable Non-Small Cell Lung Cancer Treatment

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the European Union (EU) for the treatment of adult...

April 07, 2025 | Monday | News
AVITA Medical Launches Cohealyx™ in the U.S., Expanding Portfolio for Transformative Acute Wound Care

AVITA Medical, Inc., a leading therapeutic acute wound care company delivering transformative solutions, announced the U.S. commercial launch of Cohealyx&t...

April 07, 2025 | Monday | News
Mesoblast Confirms U.S. Tariff Exemption for Allogeneic Cellular Products, Including Ryoncil® and Revascor®

Mesoblast, global leader in allogeneic cellular medicines for inflammatory diseases, provided an update on the status of its products in relation to the U....

April 04, 2025 | Friday | News
Thermo Fisher Scientific Launches Krios 5 Cryo-TEM Revolutionizing Structural Biology with Enhanced Throughput and AI Automation

Thermo Fisher Scientific, the world leader in serving science, has introduced the Thermo Scientific™ Krios™ 5 Cryo-TEM. This next-generati...

April 03, 2025 | Thursday | News
Genentech Reports Phase III MUSETTE Trial Results for Ocrevus® Showing No Additional Benefit from Higher Dose in Relapsing MS

Genentech, a member of the Roche Group, announced  that the Phase III MUSETTE trial comparing a high dose of Ocrevus® (ocrelizumab) intraveno...

April 03, 2025 | Thursday | News
Roche Reports Phase III MUSETTE Trial Results Showing No Additional Benefit from Higher Dose of OCREVUS® in Relapsing MS

Roche announced that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently approved OC...

April 03, 2025 | Thursday | News
Yingli Pharma Receives FDA Clearance to Launch Phase 3 Trial for Linperlisib in Relapsed/Refractory PTCL

Shanghai Yingli Pharmaceutical Co., Ltd., a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic, and immune dis...

April 02, 2025 | Wednesday | News
Merck Exercises Global Commercialization Option for Pimicotinib, Marking a Milestone in Partnership with Abbisko Therapeutics

Abbisko Therapeutics Co., Ltd. announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fe...

April 01, 2025 | Tuesday | News
CHMP Recommends Opdivo® for EU Approval as Neoadjuvant and Adjuvant Treatment for Resectable NSCLC

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a...

March 31, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close